ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387

Its studies are mostly in Neoplasms, led by Johnson & Johnson.

Furthest: phase 1, since Dec 12, 20231 company-led study, 1 open or runningNext primary completion: Mar 16, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson11 open or runningphase 1since Dec 12, 2023Dec 12, 2023Mar 16, 2027phase 1 · NCT06178614
  • Named in Johnson & Johnson’s own pipeline as JNJ-0387, phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2023First study: phase 1 study in NeoplasmsFirst studyNCT06178614 · 200 planned · United States, France, Spain

Ahead

  1. Mar 16, 2027Primary completion: phase 1 study in NeoplasmsNCT06178614

TargetBeta

“A human bispecific antibody directed against both ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3; NPP3; B10; PDNP3; CD203c; PD-IBETA) and the T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-ENPP3/anti-C…”NCIt, read by Claude

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06178614Neoplasms · United States, France, Spain1RecruitingMar 16, 2027200

How it is read

Names in the registry

  • “JNJ-87890387”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.